Literature DB >> 9305711

Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma.

P Althausen1, A Althausen, L C Jennings, H J Mankin.   

Abstract

BACKGROUND: The purpose of this study was to analyze the survival of 38 cases of metastatic renal cell carcinoma with secondary osseous metastases treated at the Orthopaedic Oncology Unit of the Massachusetts General Hospital. The survival was analyzed because it seemed to be considerably longer than any reported previously in the literature.
METHODS: Survival was analyzed with respect to age, gender, site of primary tumor, presence of pathologic fracture, disease free interval, initial presentation with metastasis, solitary versus multiple metastases, and axial versus appendicular metastases.
RESULTS: Survival for the entire group was 90% at 6 months, 84% at 1 year, 55% at 5 years, and 39% at 10 years. Age, gender, and presence of pathologic fracture had no influence on survival. Presentation without metastases, long disease free interval between nephrectomy and first metastases, appendicular skeletal location, and solitary metastases were all correlated with longer survival.
CONCLUSIONS: In the authors' view, patients with the characteristics correlated with longer survival are appropriate candidates for aggressive surgical resection of bone metastasis.

Entities:  

Mesh:

Year:  1997        PMID: 9305711

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Authors:  Roberto Iacovelli; Daniele Santini; Mimma Rizzo; Alessandra Felici; Matteo Santoni; Elena Verzoni; Cristina Masini; Francesco Massari; Nicola Calvani; Alessandra Mosca; Giuseppe Procopio
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Malignant bone tumors in Kuwait: a 10-year clinicopathological study.

Authors:  K C Katchy; F Ziad; S Alexander; H Gad; M Abdel Mota'al
Journal:  Int Orthop       Date:  2005-09-29       Impact factor: 3.075

3.  [Proximal and total femur replacement].

Authors:  P H Pennekamp; D C Wirtz; H R Dürr
Journal:  Oper Orthop Traumatol       Date:  2012-07       Impact factor: 1.154

Review 4.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

Review 5.  Acrometastases.

Authors:  Andreas F Mavrogenis; George Mimidis; Zinon T Kokkalis; Eirini-Sofia Karampi; Irene Karampela; Panayiotis J Papagelopoulos; Apostolos Armaganidis
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-08

6.  [Subtrochanteric renal cell carcinoma metastasis: implantation of a femoral head preserving prosthesis].

Authors:  A S Spiro; L Grossterlinden; J Zustin; J M Rueger; M H Priemel
Journal:  Orthopade       Date:  2011-03       Impact factor: 1.087

Review 7.  [Prognosis-adapted surgical management of bone metastases].

Authors:  S Utzschneider; P Weber; A Fottner; B Wegener; V Jansson; H R Dürr
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

8.  [Surgical treatment of pathologic fractures of the humerus and femur].

Authors:  G Gruber; M Zacherl; A Leithner; C Giessauf; M Glehr; H Clar; R Windhager
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

9.  Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.

Authors:  Yosuke Yasuda; Yasuhisa Fujii; Takeshi Yuasa; Shinichi Kitsukawa; Shinji Urakami; Shinya Yamamoto; Junji Yonese; Shunji Takahashi; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2012-09-11       Impact factor: 3.402

10.  Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases.

Authors:  Attila Szendroi; Elek Dinya; Magdolna Kardos; A Marcel Szász; Zsuzsanna Németh; Katalin Ats; János Kiss; Imre Antal; Imre Romics; Miklós Szendroi
Journal:  Pathol Oncol Res       Date:  2009-07-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.